Table A1.

Decision Clarification Module

Decision Model	Decision Scenario	Decision Type	Comparator	Costing	Intended Use Stratification*
					Tier 1	Tier 2
A	Single technology/drug under review, de-listing of previously approved candidate drugs not an option	Appropriateness only (ie, does not involve a funding decision or recommendation)	Benchmark against credible alternative(s)	Cost models not required
B	Single technology/drug under review, de-listing of previously approved candidate drugs not an option	Appropriateness and funding	Benchmark against credible alternative(s)	At least one cost model required	Curalib (A)
C	Several competing new drugs under review, de-listing of previously approved candidate drugs not an option	Appropriateness only	Rank against one another	Cost model not required
D	Several competing new drugs under review, de-listing of previously approved drugs not an option	Appropriateness and funding	Rank against one another	At least one cost model required		Pallialib (B)
E	Single drug only, de-listing of prior approved drugs is an option	Appropriateness only	Benchmark against a prior approved candidate drug or rank against several prior drugs	Cost model not required
F	Single drug only, de-listing of prior approved drugs is an option	Appropriateness and funding	Benchmark against prior approved drug or rank against several prior drugs	At least one cost model required
G	Several competing drugs, de-listing of prior approved drugs is an option	Appropriateness only	Rank against currently competing drugs and against prior approvals	Cost model not required
H	Several competing drugs, de-listing of prior approved drugs is an option	Appropriateness and funding	Rank against currently competing drugs and against prior approvals	At least one cost model required

NOTE. Tier 1 indicates adjuvant or curative treatment; tier 2, palliative treatment for advanced metastatic disease.